1 / 25

Evolution of Mechanical Circulatory Support: From the Balloon Pump to the Destination Ventricular Assist Device

Explore the history and evolution of mechanical circulatory support devices, from the balloon pump to the first artificial hearts and destination VADs. Discuss the clinical implications and future potential of these devices.

kherring
Download Presentation

Evolution of Mechanical Circulatory Support: From the Balloon Pump to the Destination Ventricular Assist Device

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Evolution of Mechanical Circulatory Support – From the Balloon Pump to the Destination Ventricular Assist Device Charles Hoopes MD Jason Alexander Gill Professor in Thoracic Surgery Section Chief, Heart and Lung Transplant/Mechanical Circulatory Support Director, UK Comprehensive Transplant Center University of Kentucky Lexington, KY An Equal Opportunity University

  2. Evolution of Mechanical Circulatory Support – From the Balloon Pump to the Destination Ventricular Assist Device Objectives: Discuss the history of mechanical circulatory support devices from the balloon pump to the first artificial hearts and destination VADs. Describe the evolution of the mechanical assist device from early conception to today’s current technology in successful treatment of advanced heart therapy. Describe the clinical implications for implantation of devices and recovery and what issues future devices may solve. I have no financial disclosures I have no financial relationship with any of the technologies discussed I will not discuss any off label use of current technologies Charles Hoopes MD Jason Gill Professor in Thoracic Surgery Section Chief, Cardiopulmonary Transplant/Mechanical Circulatory Support Director, UK Transplant Center University of Kentucky An Equal Opportunity University

  3. Conceptual eras of mechanical circulatory support.. 1812 Le Gallois “parts of the body may be preserved by external perfusion” Etienne-Jules Marey (Paris,1881) – physician, inventor .. the 1st “artificial heart Guillotined head of a dog in perfusion experiments of Brukhonenko and Tchetchuline. This preparation relied on gas exchange from a second donor dog's lungs. Diaphragm-like pumps pumped blood into the recipient dog's carotid arteries. Dog heads perfused in this manner remained functional for a few hours. (Reprinted from Brukhonenko S, Tchetchuline S. Experiences avec la tete isolee du chien.1.Technique et conditions des experiences. J Physiol Pathol Gen 1929;27:42) ..a “biological oxygenator”

  4. Intellectual origins of “mechanical assist” and “circulatory support”… “Experimentally, it is possible to completely replace the heart with an artificial heart, and animals have been known to survive as long as 36 hours. This idea, I am sure, could be reached to full fruition if we had more funds to support more work, particularly in the bioengineering area” DeBakey (1963) Senator Lister Hill’s Subcommittee on Health In Jan of 1964 James Hardy consented the sister of Boyd Rush – a 68 yo comatose deaf mute with ischemic heart failure and lower extremity gangrene – for “the insertion of a suitable heart transplant if such should be available. Rush decompensated and was placed on cardiopulmonary bypass. In the absence of a viable donor Hardy transplanted the heart of a 45 kg chimpanzee. The heart provided hemodynamic support for 90 minutes… May 1965 “..surgeons at Baylor hailed the Jackson transplant. The Baylor surgeons say there are two solutions for support of the failing heart..transplants from humans or animals and artificial hearts. The Baylor group is concentrating its efforts on developing an artificial heart.” Associated Press, 25 Jan 1964

  5. Physiologic basis… “..mechanical pumping of blood to viscera previously inadequately perfused … reducing the workload and oxygen consumption of the myocardium” Ann Review Med 1966

  6. Evolution of Mechanical Circulatory Support… 1981 1982 1965 1969 1936 1968 As socio-political history…

  7. Evolution of Mechanical Circulatory Support… HeartWare Thoratec Abiomed As medical technology…

  8. Evolution of Mechanical Circulatory Support… Historical context oxygenators and pumps, biological and mechanical Application (why are you doing this and what do you want) “moratorium of decision” (non-durable ) “bridge to recovery” (non-durable and durable) “bridge to transplant” (non-durable and durable) “destination therapy” (durable) Deployment (how do we do it and when do we try) Problems (general, device specific, and evolving) As clinical medicine…

  9. Historical “truisms” in mechanical circulatory support (MCS)… Deployment of MCS technologies in the context of medical futility results in futile deployment of technology… MCS is capable of resuscitation, not reanimation MCS technology restores hemodynamics (>86%) but may not alter survival depending upon the specifics of deployment “Unnecessary surgery” performed well has excellent outcomes… device technology should be deployed based upon clinical trajectory and the natural history of the disease process Physiology always trumps engineering.. MCS can support patients awaiting good clinical decision making but is ineffective in supporting bad clinical decisions

  10. 3 October 1930 “..at 8AM respirations ceased and the blood pressure could not be obtained. Within 6 min and 30 sec Dr. Churchill opened the chest, incised the pulmonary artery, extracted a large pulmonary embolus, and closed the incised wound..” “the idea occurred to me if it were possible to remove continuously some of the blue blood from the patient’s swollen veins, put oxygen into the blood and allow carbon dioxide to escape from it, and then to inject continuously the now red blood back into the patients arteries, we might have saved her life. We would have bypassed the obstructing embolus and performed part of the work of the patients heart and lungs outside the body.” JH Gibbon Gibbon JH Jr (1939) The maintenance of life during experimental occlusion of the pulmonary artery followed by survival. Surg Gynecol Obstet 69:604

  11. The original “TandemHeart”… Dennis et al (1962) Ann Surg 156:623

  12. The Percutaneous Ventricular Assist Device in Severe Refractory Cardiogenic Shock Cardiogenic shock: SBP<90mmHg, CI<2 L/min, inadequate end organ perfusion with IABP/pressor support 88 ischemic, 37 non-ischemic (9 myocarditis) pLVAD (TandemHeart): SVO2>70%, MAP>60mmHg, AoV DOS 5.8 days…MSOF(n=31),CVA(n=8) Pre pLVAD Post pLVAD Cardiac index, l/(min·m2) 0.52 (0.8) 3.0 (0.9) SBP, mm Hg 75 (15) 100 (15) DBP, mm Hg 30 (20) 65 (20) MAP, mm Hg 45 (20) 81 (15) HR, beats/min 105. 118.0 SVO2, % 49 (11.5) 69.29 (10) PCWP, mm Hg 31.52 17.29 PAP mm Hg 39.16 26.70 Lactic acid, mg/dl 24.5 (74.25) 11.0 (12) LDH, U/dl602 (630) 416.5 (335) pH 7.22 0.14 7.44 0.06 Urine output, ml/day 70.3 1200 Hemoglobin 11 10.25 Kar et al (2011) JACC 57:688

  13. “Pumping improved two patients' circulatory status; one survived. Two patients died before pumping could begin; in another, an abdominal aortic aneurysm prevented insertion of the pump… Kantrowitz et al (1968) JAMA 203:135

  14. RETROSPECTIVE ANALYSIS OF 286 PATIENTS REQUIRING CIRCULATORY SUPPORT WITH THE INTRAAORTIC BALLOON PUMP “From 1972 through 1974, we implanted the pump in 34 patients. Of those patients, only 2 (1 in 1973 and 1 in 1974) survived until explantation, and only 1 (the patient in 1974) survived to discharge. Yet the intraaortic balloon pump remains essentially unchanged today, and survival rates of 70% to 80% can be expected when the device is implanted in appropriately selected patients … This experience emphasizes the danger of premature randomized studies, which can expose technology to errors that are manmade rather than inherent.” OH Frazier (2005) Tex Heart Inst J 32:60 Johnson et al (1977) Cardiovasc Dis 4(4):428–436. Device function must match patient need… preservation of end organ perfusion (survival) and capacity for functional myocardial recovery The timing of implantation is critical to patient survival… Mechanical circulatory support (MCS) as a clinical program, not an isolated procedure

  15. “Escalation therapy” criteria and MCS application…and deployment Hemodynamic instability: CI<1.8, CPO<0.53, PCWP>18 FiO2/PaO2<300, “high” inotropy CPO: MAP x CO/451 0.53 Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry Fincke (2004) JACC 44:340

  16. Ben Roe and the UCSF “artificial heart” circa 1970 post LVAD

  17. Left ventricular assist vs. biventricular replacement… Durable vs non-durable applications Heartware (impellar) Syncardia TAH AbioCor TAH Heartmate II (axial flow)

  18. Evolution of implantable mechanical cardiac assist technologies…… II III I

  19. The complexity of mechanical circulatory support technologies represents… epidemiology…a significant clinical need…cardiogenic shock is highly morbid and frequently lethal (>55%) absence of a common effective therapy… anecdotal experience not supported by clinical trials pkVO2 12-16 ml/kg/min variability of clinical application… Ongoing RCT in low risk pts with pkVO2 12-16 ml/kg/min “Crash and burn” will get bridge to durable device 1. Critical cardiogenic shock 2. Progressive decline 3. Stable inotrope dependent 4. Recurrent advanced disease 5. Exercise intolerant 6. Exercise limited 7. Advanced NYHA class III Inotrope dependent

  20. Risk factors for death in patients with an implantable mechanical circulatory support device: older patient age at the time of implant (relative risk [RR] = 1.41, p < 0.001); assignment to INTERMACS Level 1 category characterized by cardiogenic shock with life-threatening hypoperfusion (RR = 1.59, p = 0.02); indicators of severe right ventricular failure, such as ascites and hyperbilirubinemia, which are clinically evident at the time of implant Pagani et al (2009) J Heart Lung Transpl

  21. INTERMACS Competing Outcomes – Level 1: Critical Cardiogenic Shock (n=186) Competing Outcomes – Level 2: Progressive Decline (n=148) Proportion of patients Transplanted 40% Transplanted Proportion of patients Dead 29% Alive Alive 26% Dead Recovery 5% Months after Device Implant Months after Device Implant Competing Outcomes – Level 3: Stable but Inotrope Dependent (n=35) Alive Proportion of patients Transplanted Dead Months after Device Implant

  22. Evolution of mechanical circulatory support…ventricular assist devices Moratorium of decision Bridge to recovery Bridge to transplant Destination (CMS) Are VADs an operation…or part of an integrated heart failure program? Slaughter M (2010) Will destination therapy be limited to large transplant centers? Texas Heart Inst J 37(5):562

  23. The evolution of mechanical cardiopulmonary support … the “learning curve” No device has ever saved or killed a patient … good physicians using good devices have done both No device program has everything … effective device programs have everything they need Device technology accomplishes nothing but facilitates everything

  24. LVAD induced remodeling: Basic science and clinical implications for recovery • * biomarkers of recovery • (genetic,structural,metabolic) • * therapeutic intervention (pre,post,and peri) • * etiology of CHF (sequential tissue) May ‘08 Inotrope dependent BNP Leftward shift of the EDPVR (structural “reverse remodeling”) Time dependent reduction in heart size (EDP of 30 mmHg, V30) Regression of cellular hypertrophy Dec ‘08 Dec ‘08 LVAD Pre-explant(12) inotropes LVAD pod1 Explant pod7(103) Explant pod1 Feb ‘09 s/p LVAD

  25. LVAD induced remodeling: Basic science and clinical implications for recovery May ‘08 Inotrope dependent Leftward shift of the EDPVR (structural “reverse remodeling”) Time dependent reduction in heart size (EDP of 30 mmHg, V30) Regression of cellular hypertrophy Dec ‘08 Dec ‘08 LVAD Feb ‘09 s/p LVAD

More Related